Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (421-430 of 477) with videos related to

Pageof 48
Sort By:
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Arthritis and Rheumatism|June 3, 2008
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisKenneth G Saag, Gim Gee Teng, Nivedita M Patkar, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Arthritis Care & Research|June 18, 2023
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus MeetingsIvan Foeldvari, Kathryn S Torok, Jordi Anton, et al.
Arthritis and Rheumatism|September 5, 2002
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging studyDaniel E Furst, Kenneth Saag, M Roy Fleischmann, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Clinical and Translational Science|January 27, 2021
Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjectsKyung-Sang Yu, In-Jin Jang, Hyeong-Seok Lim, et al.
Arthritis and Rheumatism|June 10, 2010
A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritisWenfeng Tan, Hui Wu, Jian Zhao, et al.
Pageof 48

Showing results (421-430 of 477) with videos related to

Sort By:
Pageof 48
Arthritis and Rheumatism|February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Arthritis and Rheumatism|June 3, 2008
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisKenneth G Saag, Gim Gee Teng, Nivedita M Patkar, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Arthritis Care & Research|June 18, 2023
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus MeetingsIvan Foeldvari, Kathryn S Torok, Jordi Anton, et al.
Arthritis and Rheumatism|September 5, 2002
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging studyDaniel E Furst, Kenneth Saag, M Roy Fleischmann, et al.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Clinical and Translational Science|January 27, 2021
Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjectsKyung-Sang Yu, In-Jin Jang, Hyeong-Seok Lim, et al.
Arthritis and Rheumatism|June 10, 2010
A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritisWenfeng Tan, Hui Wu, Jian Zhao, et al.
Pageof 48